Sinew Pharma Inc. (TPEX:6634)

Market Cap	3.42B
Revenue (ttm)	n/a
Net Income (ttm)	-150.37M
Shares Out	71.31M
EPS (ttm)	-2.11
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,074
Average Volume	52,416
Open	48.65
Previous Close	48.65
Day's Range	46.85 - 49.00
52-Week Range	34.30 - 72.80
Beta	-0.06
RSI	41.66
Earnings Date	Aug 11, 2025

About Sinew Pharma

Sinew Pharma Inc., a biopharmaceutical company, focuses on the development and sale of drugs for the treatment of hepatotoxicity-free acetaminophen and fatty liver diseases. The company’s products include SNP-610 drug, which is in Phase II clinical trial for treating patients with non-alcoholic steatohepatitis in Taiwan; and SNP-630 drug, for which is in Phase II clinical trial. It is also developing SNP-810 is in phase II clinical trial for use in Pain relief and fever reduction; SNP-820 is in Phase II clinical trial for antidote for acetamino...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 52
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6634